January 18, 2017

Searching for Spondyloarthritis in a Diagnostic Dead Zone

Where are the patients?

back pain

By Leonard Calabrese, DO

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Knowledge of spondyloarthritis (SpA) in our field has progressed rapidly over the past generation and in particular over the past 15 years. From the beginnings of its clinical recognition in the nineteenth century as Marie-Strumpell Disease, to the molecular discovery of the association with HLA-B27 in the early 1970s, the view of the illness has changed dramatically.

More recently, we have come to appreciate that not only is the advanced phenotype of the disease fortunately diminishingly rare, but our ability to detect and treat patients with early disease has greatly improved. Recent studies increasingly support the conclusion that with both aggressive use of NSAIDS as well as a growing list of biologic therapies, we can actually alter the natural history of the disease in many patients.

Where are the patients?

Early detection is key for patients with SpA to benefit from advanced care and treatment to control their underlying inflammatory arthritis and any formidable comorbidities. It’s common knowledge in rheumatology practice that though we believe SpA to be as common as rheumatoid arthritis (RA), we see it far less often in clinic. We hoped the recognition of nonradiographic axial spondyloarthritis, defined similarly to radiographic disease but without changes on plain x-rays, would close this recognition gap, but it has not appeared to do so. Instead, it simply highlights the epidemiologic conundrum – where are the patients?

The foundation to our answer lies in the commonness of back pain in the general population. Rheumatologists do not see a fraction of such patients. The National Health and Nutrition Examination Survey (NHANES) data on low back pain show that up to 20 percent of people have chronic back pain and, more importantly, 5 percent of the overall population has inflammatory back pain which can be a useful gateway for SpA diagnosis.

Advertisement

Recognizing SpA in primary care settings

It seems many patients with SpA are being treated for back pain in primary care, chiropractic and orthopaedic settings. A recent study examining primary care practice found that among patients with chronic low back pain < 45 years of age, up to 25 percent may have unrecognized SpA. Another study showed that up to 40 percent of patients with new onset iritis may have unrecognized SpA, and that a simple algorithm enables detection of SpA. Clearly, we need to develop creative and productive educational programs designed to help providers increase their skills at suspecting and diagnosis SpA.

Osteopathic family physicians are a vital link in the public health approach to patients with low back pain as evidence demostrates that they see a disproportionate number of patients with low back pain when compared to their allopathic counterparts. I’m currently currently working with the American Osteopathic Association and the American College of Osteopathic Family Physicians to create educational programming with specific objectives designed to detect previously unrecognized patients with SpA, optimize their diagnosis and treatment, and refer when appropriate for advanced care to rheumatologists.

Learn more at the Biologics Therapies VII Summit

To address the many learning opportunities in PsA and SpA, we will be holding a summit April 6-8, 2017, at the InterContinental Hotel and Conference Center in Cleveland, Ohio, designed for all clinicians caring for patients with autoimmune and autoinflammatory diseases. M. Elaine Husni, MD, MPH, will chair a half-day session on these disorders featuring the expertise of Dafna Gladman, MD, Michael Weisman, MD, Philip Mease, MD, and Christopher Ritchlin, MD, MPH. The summit will also highlight the hopes and challenges of precision medicine for the nearly 50 million people in the U.S. with disorders of immunity.

For registration and additional information on the Summit, visit www.ccfcme.org/biotherapiesVII.

Advertisement

This activity has been approved for AMA PRA Category 1 Credit™.

Dr. Calabrese is Director of the R.J. Fasenmyer Center for Clinical Immunology in Cleveland Clinic’s Department of Rheumatic and Immunologic Diseases.

Related Articles

psoriasis of the fingernails and psoriatic arthritis on white background
July 15, 2022
Using Patient-Reported Outcomes to Distinguish Between Low Disease Activity and Remission in Psoriatic Arthritis

Patient perceptions of disease provides valuable dimension to assessment

21-RHE-2356408-Hero-ImageOpt2-650&#215;450
September 16, 2021
Assessing Clinical Response to Treatment in Psoriatic Arthritis

Patient reported outcomes differentiate between remission and low disease activity in PsA

18-HRT-411-aspirin-650&#215;450
May 22, 2019
A Simple Clinical Risk Score for Major NSAID Toxicity

Evidence-based, internally validated method for risk evaluation

18-RHE-1125-Husni-Hero-Image-650x450pxl
October 26, 2018
Practice-Changing PRECISION Subanalyses

What rheumatologists should know

15-RHE-2814-Husni-Image-650x450pxl
November 10, 2016
Tapering DMARDs: Where are we now?

Raising more questions than answers

15-RHE-2599-Chatterjee-Hero-Image-690x380pxl
November 11, 2015
Lung Effects of Anti-PM-Scl Antibody: Analysis Yields Important Questions for Prospective Study

New insights into PAH and ILD in patients with the antibody

15-RHE-532-Husni-Hero-Image-690x380pxl
April 29, 2015
Guidance at Last on Managing Comorbidities of Psoriatic Arthritis

GRAPPA provides first expert recommendations

Medical illustration of hand with discolored fingers
February 27, 2024
Coexistence of Erythromelalgia and Raynaud’s Phenomenon

Treatment strategies require understanding of pathomechanisms

Ad